# Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

> **NCT05675787** · PHASE2 · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 82 (estimated)

## Conditions studied

- Atypical Endometrial Hyperplasia
- Endometrial Carcinoma Stage I

## Interventions

- **DRUG:** Medroxyprogesterone acetate + Atorvastatin

## Key facts

- **NCT ID:** NCT05675787
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-06
- **Primary completion:** 2025-08-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2024-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05675787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05675787, "Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05675787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*